None
Quote | Bioinvent Ab (OTCMKTS:BOVNF)
Last: | $4.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.70 |
High: | $0 |
Low: | $0 |
Volume: | 14 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bioinvent Ab (OTCMKTS:BOVNF)
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
Message Board Posts | Bioinvent Ab (OTCMKTS:BOVNF)
Subject | By | Source | When |
---|---|---|---|
Transgene and BioInvent Announce Clinical Trial Collaboration and | ancientacid | investorshub | 06/28/2022 8:02:31 PM |
Exelixis-BioInvent Establish Immuno-Oncology Pact | ancientacid | investorshub | 06/17/2022 7:28:22 PM |
The global non-Hodgkin lymphoma treatment market size is | ancientacid | investorshub | 01/28/2021 11:17:25 PM |
BioInvent Phase I/IIa data suggest BI-1206 restores activity | ancientacid | investorshub | 01/28/2021 2:31:32 PM |
BioInvent secures $3M on selection of antibodies under | ancientacid | investorshub | 01/28/2021 2:29:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Bioinvent Ab Company Name:
BOVNF Stock Symbol:
OTCMKTS Market:
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...